Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

DC-CIK cell and anti-PD-1 antibody composition and application thereof

An antibody composition, DC-CIK technology, applied in the field of tumor microenvironment, tumor immunotherapy, and immunology, can solve the problem of no relevant research reports on DC-CIK cells and anti-PD-1 antibody composition specific methods, no research Report on therapeutic effects and other issues to achieve disease stabilization, enhanced activity, enhanced activation effects

Active Publication Date: 2017-06-27
珠海横琴壹加医疗健康管理有限公司
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the many differences between CIK cells and CIK cells in the distribution of cell subsets and cytokine secretion, there is no research report on the therapeutic effect of DC-CIK cells combined with immune checkpoint blockers, and there is no related research report on DC-CIK cells and anti-immune checkpoint blockers. Specific methods, therapeutic effects and toxic and side effects of PD-1 antibody composition applied in human body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DC-CIK cell and anti-PD-1 antibody composition and application thereof
  • DC-CIK cell and anti-PD-1 antibody composition and application thereof
  • DC-CIK cell and anti-PD-1 antibody composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Design of Clinical Trials

[0029] This example carried out a phase I single-arm prospective clinical trial study. The relevant cases selected patients with advanced refractory malignant tumors who had progressed after conventional treatment (surgery, radiotherapy, chemotherapy, and targeted therapy). DC-CIK cells were used for observation. The safety, feasibility and effectiveness of the clinical application of the anti-PD-1 antibody composition in the treatment of these patients.

[0030] (1) Inclusion of research objects:

[0031] 1) Inclusion criteria:

[0032] ① Patients with advanced refractory malignant tumors, including primary hepatocellular carcinoma, clear cell renal cell carcinoma, bladder cancer, colon cancer, non-small cell lung cancer, etc.; ② Age 18-75 years old; ③ Expected survival > 3 months; ④ ECOG score 0 or 1 point; ⑤ Normal heart, lung, liver and kidney functions; ⑥ Sufficient bone marrow reserve capacity and normal prothrombin; contr...

Embodiment 2

[0044] Example 2: Specific methods for treating cancer with DC-CIK cells and anti-PD-1 antibody composition

[0045] After determining the research object, in this embodiment, the peripheral blood of the patient will be extracted to separate PBMC, and the DC-CIK cells will be cultured, incubated with anti-PD-1 antibody, and then reinfused into the patient for treatment.

[0046] (1) Materials and methods:

[0047] 1) Preparation of DC-CIK cells and anti-PD-1 antibody composition

[0048] After carefully checking the blood samples and the relevant information of the patient, draw 50ml of peripheral blood from the patient, centrifuge at 800g×8min, collect autologous plasma, inactivate it in a water bath at 56°C for 30min, place it at 4°C for 15min, take 800g×8min, and take the supernatant plasma (approx. 20ml) for use. Under the normal working condition of the ultra-clean workbench, dilute the peripheral blood cells collected by centrifugation to 60ml with 0.9% normal saline f...

Embodiment 3

[0061]Example 3: Clinical efficacy and safety evaluation of DC-CIK cells and anti-PD-1 antibody composition in the treatment of cancer

[0062] (1) Efficacy evaluation:

[0063] Patients included in this clinical trial study had measurable target lesions. Lesions were evaluated by CT imaging at baseline (one month before treatment), treatment period (every 3 months), and follow-up period after treatment (every 6 months).

[0064] 1) Efficacy evaluation criteria

[0065] Response Evaluation Criteria in Solid Tumors (RECIST) was used for efficacy evaluation. First determine the sum of the lengths of all measurable target lesions at baseline as the reference baseline for effective remission records, and then evaluate the effective remission of the disease according to the changes in the target lesions relative to the baseline level during the treatment period or follow-up period after treatment.

[0066] 2) Criteria for effective mitigation

[0067] Response criteria include ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the fields of immunology, tumor microenvironment and tumor immnuotherapy and provides a DC-CIK cell and anti-PD-1 antibody composition which is used for preparing immune drugs for treating cancers or delaying cancer development. The invention provides a combined immune composition for treating cancers, and the composition is formed by an effective dose of DC-CIK cells and an anti-PD-1 antibody. According to the combined immune composition, the immunocompetence for killing the cancer cells in a patient body can be effectively enhanced, and a cancer clinic treatment effect can be improved or the cancer development can be delayed hopefully.

Description

technical field [0001] The invention belongs to the fields of immunology, tumor microenvironment and tumor immunotherapy, and relates to a combination of DC-CIK (cytokine-induced killer cells activated by dendritic cells) cells and anti-PD-1 (programmed death receptor 1) antibodies The use of the drug, specifically relates to the use of DC-CIK cells and anti-PD-1 antibody composition for the preparation of immune drugs. Background technique [0002] With the development of industrialization, the aggravation of environmental pollution, and the effects of external factors such as smoking, bad life and eating habits, the incidence of tumors in the world is increasing year by year, and it has become the first cause of death of urban residents in my country. [0003] In recent years, due to the development of comprehensive treatment methods such as surgery, chemotherapy, radiotherapy and immunotherapy, tumors have gradually become a controllable disease. In particular, immunothe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K35/17A61P35/00
CPCA61K9/0019A61K35/17A61K39/39566
Inventor 夏建川潘求忠陈昶泷
Owner 珠海横琴壹加医疗健康管理有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com